CClinicalTrials.gg
Sign In
RecruitingNCT07304154Updated Aug 14, 2026

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

A Phase 1 interventional study of KITE-363 and Fludarabine in Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis and Multiple Sclerosis, sponsored by Kite, A Gilead Company. Recruiting at 8 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Kite, A Gilead Company · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 5 months later.
Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases.

The primary objectives of this study are:

  • To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases
  • To determine the recommended dose for Phase 1b.
  • To evaluate the preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases.
02

Conditions studied

  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Myasthenia Gravis
  • Multiple Sclerosis
03

In context

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

129 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 49 are open to participants now.

This study's planned enrollment of 52 is above the median of 40 across 82 interventional studies indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Lead sponsor

Kite, A Gilead Company is the lead sponsor of 36 studies on the registry; 7 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 14 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Reproductive status-related eligibility and contraception requirements:

    • Participants must agree to use protocol-specified method(s) of contraception where applicable

Inclusion Criteria for multiple sclerosis (MS):

MS (Relapsing and progressive forms):

  • Diagnosed with MS according to the 2017 revision of the McDonald diagnostic criteria

Relapsing forms of MS (relapsing-remitting multiple sclerosis (RRMS), active secondary-progressive multiple sclerosis (aSPMS)):

  • Inadequate response to previous therapies is defined as evidence of breakthrough disease activity within 12 months prior to screening while on high efficacy disease-modifying therapy (DMT) OR Inadequate response to previous therapies defined as intolerance to ≥ 2 DMTs due to side effects prohibiting the chronic use of the DMT.
  • Expanded Disability Status Scale (EDSS) 0 to 5.5

Progressive forms of MS (primary-progressive multiple sclerosis (PPMS) and non-active secondary-progressive multiple sclerosis (naSPMS)):

  • Inadequate response to previous therapies is defined as evidence of disease progression within 12 months prior to screening despite standard of care therapy for naSPMS or despite ocrelizumab, where available, for PPMS
  • Absence of clinical relapses for at least 24 months
  • No evidence of Gadolinium enhancing (GadE+) on magnetic resonance imaging (MRI) brain at screening or baseline
  • EDSS of 3 to 6.5 who are ambulatory

Inclusion Criteria for myasthenia gravis (MG):

  • Documentation of autoantibodies against acetylcholine receptor (AChR), muscle-specific kinase (MuSK), or low-density lipoprotein receptor-related protein 4 (LRP4)
  • Diagnosis of MG with generalized weakness meeting criteria as defined by the Myasthenia Gravis Foundation of American (MGFA) classification of II- IV at screening
  • Myasthenia Gravis Activities of Daily Living (MG-ADL) score ≥ 6 (> 50% of the total score due to non-ocular symptoms)
  • Quantitative Myasthenia Gravis (QMG) score ≥ 10
  • Inadequate response to previous therapies while taking at least 2 classes of immunosuppressants (ie, steroids, azathioprine (AZA), mycophenolate mofetil (MMF), intravenous immunoglobulin (IVIg), biologics (eg, rituximab, anti-neonatal fragment crystallizable (Fc) receptor (FcRN) class, and anti-complement class))
  • Thymectomy allowed if completed ≥ 12 months prior to screening

Inclusion Criteria for chronic inflammatory demyelinating polyneuropathy (CIDP):

  • Probable or definite CIDP as defined by the 2010 European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria, relapsing or progressive forms
  • CIDP Disease Activity Status (CDAS) score ≥ 3 at screening
  • Inflammatory neuropathy cause and treatment (INCAT) score ≥ 3
  • Inadequate response to previous therapies despite standard of care therapy (ie, steroids, IVIg, subcutaneous immunoglobulin (SCIg), plasmapheresis exchange (PLEX), rituximab, or anti FcRN) OR Unable to tolerate standard of care due to side effects with ongoing disease activity
  • Except for nodal/paranodal CIDP, historical documentation of objective improvement in the past 24 months while on IVIg, SCIg, PLEX, or anti-FcRN OR Historical documentation of objective disease worsening in the past 24 months when IVIg, SCIg, PLEX, or anti-FcRN has been reduced or interrupted

Key Exclusion Criteria:

  • History or presence of central nervous system (CNS) or peripheral nervous system disorders before enrollment that may impact cognition, strength, or cause weakness
  • History of autologous or allogeneic stem cell transplant and/or organ transplant

Exclusion Criteria for MS:

  • Cohort 1 or 2; inability to complete 9-hole Peg Test (9-HPT) in \< 240 seconds and Timed 25 foot Walk (T25FW) \< 150 seconds
  • History of hypersensitivity to parenteral administration of gadolinium-based contrast agents
  • Any renal condition that would preclude the administration of gadolinium (for the relapsing forms of MS and progressive forms of MS)
  • Any contraindication to lumbar puncture (LP) (for the relapsing forms of MS and progressive forms of MS)

Exclusion Criteria for MG:

  • Current myasthenic crisis not effectively controlled within 2 weeks before enrollment
  • Thymectomy performed within 12 months of baseline

Exclusion Criteria for CIDP:

  • Pure sensory CIDP and focal CIDP
  • Polyneuropathy of other causes

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Phase 1a: KITE-363 (Dose Escalation)

    Participants with relapsing forms of multiple sclerosis (RMS), progressive forms of multiple sclerosis (PMS), myasthenia gravis (MG), and/or chronic inflammatory demyelinating polyneuropathy (CIDP) will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by infusion of KITE-363 chimeric antigen receptor (CAR) transduced autologous T cells at a single dose level, with different participants receiving sequential dose-escalation levels to find the Phase 1b recommended dose.

    Biological: KITE-363 · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Phase 1b: KITE-363 (Dose Expansion)

    Participants with RMS, PMS, MG, and/or CIDP will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed Phase 1a recommended dose of KITE-363 CAR T cells.

    Biological: KITE-363 · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

  • BiologicalKITE-363

    A single infusion of CAR-transduced autologous T cells administered as intravenous infusion.

  • DrugFludarabine

    Administered intravenously

  • DrugCyclophosphamide

    Administered intravenously

06

What researchers measure

Primary outcomes

  1. Phase 1a: Percentage of Participants Experiencing Treatment-emergent Adverse Event (TEAEs)

    Time frame: Up to 2 years

  2. Phase 1a: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363

    Time frame: Up to 28 days

  3. Phase 1b: (All Cohorts) Percentage of Participants Experiencing TEAEs

    Time frame: Up to 2 years

  4. Phase 1b: Relapsing Forms of MS (RRMS) and (aSPMS): Number of New T1 Gadolinium Enhancing (GadE+) Lesions on Magnetic Resonance Imaging (MRI) at Week 12

    This will be reported in participants with relapsing forms of Multiple Sclerosis MS (RRMS) and (aSPMS).

    Time frame: Week 12

  5. Phase 1b: Relapsing Forms of MS (RRMS and aSPMS): Number of New and/or Enlarging T2 Lesions on MRI at Week 12

    Time frame: Week 12

  6. Phase 1b: Progressive Forms of MS (PPMS) and (naSPMS): Time to Onset of Confirmed Disability Progression Over 12 Weeks (CDP-12)

    Time frame: Up to 2 years

  7. Phase 1b: Myasthenia Gravis (MG): Proportion of Participants of MG Activities of Daily Living (MG-ADL) Responders

    The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden.

    Time frame: Up to Week 24

  8. Phase 1b: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Proportion of Participants with Confirmed Evidence of Clinical Improvement at Week 24

    Clinical improvement will be analyzed using inflammatory neuropathy cause and treatment (INCAT) scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate clinical improvement.

    Time frame: Week 24

Secondary outcomes

  1. Relapsing forms of MS (RRMS and aSPMS): Annual Relapse Rate

    Proportion of participants with annual relapse.

    Time frame: Up to 2 years

  2. Relapsing Forms of MS (RRMS and aSPMS): Proportion of Participants With CDP-12

    Time frame: Up to 2 years

  3. Relapsing Forms of MS (RRMS and aSPMS): Proportion of Participants With CDP-24

    Time frame: Up to 2 years

  4. Relapsing Forms of MS (RRMS and aSPMS): Time to Onset of CDP-12

    Time frame: Up to 2 years

  5. Relapsing Forms of MS (RRMS and aSPMS): Time to Onset of CDP-24

    Time frame: Up to 2 years

  6. Progressive forms of MS (PPMS and naSPMS): Proportion of Participants with No Evidence of Disease Activity (NEDA)

    Time frame: Up to 2 years

  7. Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Expanded Disability Status Scale (EDSS) Score Over Time

    EDSS is scale used to measure disability and disease progression in participants with MS. It ranges from 0 (normal neurological exam) to 10 (death due to MS) in 0.5-point increments.

    Time frame: Up to 2 years

  8. Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Timed 25-foot Walk (T25FW) Score Over Time

    The T25FW is a performance-based measure used in people with MS to assess walking speed and mobility. Lower times indicate better walking ability, while longer times reflect greater impairment.

    Time frame: Up to 2 years

  9. Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in 9-hole Peg Test Dominant/Non-dominant (9-HPT D/ND) Score Over Time

    The 9-HPT assesses hand dexterity and fine motor function by timing how long it takes a participant to place and remove nine pegs from a board. Faster times indicate better function, while slower times reflect greater disability.

    Time frame: Up to 2 years

  10. Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Symbol Digit Modalities Test (SDMT) Score Over Time

    SDMT is a performance-based cognitive assessment to measure information processing speed. The score is the number of correct responses completed in the time limit, with higher scores indicating better cognitive processing speed.

    Time frame: Up to 2 years

  11. Progressive Forms of MS (PPMS and naSPMS): Proportion of Participants with CDP-12

    Time frame: Up to 2 years

  12. Progressive Forms of MS (PPMS and naSPMS): Proportion of Participants with CDP-24

    Time frame: Up to 2 years

  13. Progressive forms of MS (PPMS and naSPMS): Time to Onset of CDP-24

    Time frame: Up to 2 years

  14. Progressive forms of MS (PPMS and naSPMS): Number of new and Enlarging T2 Lesions on MRI

    Time frame: Up to 2 years

  15. Relapsing forms of MS (RRMS and aSPMS): Percentage of Participants With NEDA

    Time frame: Up to 2 years

  16. Progressive forms of MS (PPMS and naSPMS): Change From Baseline in EDSS Over Time

    EDSS is scale used to measure disability and disease progression in participants with MS. It ranges from 0 (normal neurological exam) to 10 (death due to MS) in 0.5-point increments.

    Time frame: Up to 2 years

  17. Progressive forms of MS (PPMS and naSPMS): Change From Baseline in T25FW Over Time

    The T25FW is a performance-based measure used in people with MS to assess walking speed and mobility. Lower times indicate better walking ability, while longer times reflect greater impairment.

    Time frame: Up to 2 years

  18. Progressive forms of MS (PPMS and naSPMS): Change From Baseline in 9-HPT D/ND Over Time

    The 9-HPT assesses hand dexterity and fine motor function by timing how long it takes a participant to place and remove nine pegs from a board. Faster times indicate better function, while slower times reflect greater disability.

    Time frame: Up to 2 years

  19. Progressive forms of MS (PPMS and naSPMS): Change From Baseline in SDMT Over Time

    SDMT is a performance-based cognitive assessment to measure information processing speed. The score is the number of correct responses completed in the time limit, with higher scores indicating better cognitive processing speed.

    Time frame: Up to 2 years

  20. MG: Proportion of Participants With at Least a 2-Point or 5 Point Improvement in MG-ADL Score up to Week 24

    The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden.

    Time frame: Up to 24 weeks

  21. MG: Change From Baseline in MG-ADL Score at Week 24

    The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden.

    Time frame: Baseline, Week 24

  22. MG: Proportion of Participants With Minimal Symptom Expression (MG-ADL Score of 0 or 1 Point)

    The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden.

    Time frame: Up to 2 years

  23. MG: Proportion of Participants With at Least a 3-point or 5-point Improvement in Medical Research Council (QMG) Score up to Week 24

    The QMG test is a standardized quantitative strength scoring system developed specifically for MG. The total QMG score is the sum of the scores for 13 items, with a possible maximum score of 39. A higher score indicates more severe disease involvement, while a lower score suggests less functional impairment.

    Time frame: Baseline, Week 24

  24. MG: Change From Baseline in QMG Score to Week 24

    The QMG test is a standardized quantitative strength scoring system developed specifically for MG. The total QMG score is the sum of the scores for 13 items, with a possible maximum score of 39. A higher score indicates more severe disease involvement, while a lower score suggests less functional impairment.

    Time frame: Baseline, Week 24

  25. MG: Proportion of Participants With at Least a 3-Point Improvement in MG-C Score up to Week 24

    MG-C scale is a tool that measures disease severity in MG. The total score ranges from 0 to 50, with higher scores indicating greater impairment.

    Time frame: Baseline, Up to 24 weeks

  26. Change From Baseline in MG-C Scale Score at Week 24

    MG-C scale is a tool that measures disease severity in MG. The total score ranges from 0 to 50, with higher scores indicating greater impairment.

    Time frame: Baseline, Week 24

  27. MG: Number of Participants With Changes in Myasthenia Gravis Foundation of American Post-Intervention Status (MGFA-PIS), Including Minimal Manifestation, Complete Stable Remission, Pharmacologic Remission

    The MGFA-PIS is a standardized classification system which categorizes outcomes into distinct states such as complete stable remission (CSR), pharmacologic remission (PR), minimal manifestations (MM), improved, unchanged, worse, and exacerbation. CSR indicates no symptoms or signs for at least one year without therapy, while MM reflects minimal weakness without functional limitation.

    Time frame: Up to 2 years

  28. CIDP: Time to First Adjusted INCAT Deterioration

    INCAT is a clinician-administered tool used to assess functional disability in participants with CIDP. The total score ranges from 0 to 10, where higher scores indicate greater disability and lower score would indicate clinical improvement.

    Time frame: Up to 2 years

  29. CIDP: Proportion of Participants With Confirmed Evidence of Clinical Improvement

    Clinical improvement will be analyzed using INCAT scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement.

    Time frame: Week 48

  30. CIDP: Proportion of Participants With Evidence of Clinical Improvement

    Clinical improvement will be analyzed using inflammatory Rasch-built overall disability scale (I-RODS) scale. I-RODS is a scale that assesses activity and participation limitations in people with CIDP. The score ranges from 0 to 48, with higher scores indicating better functional ability.

    Time frame: Up to week 48

  31. CIDP: Time to Disease Progression by I-RODS

    I-RODS is a scale that assesses activity and participation limitations in people with CIDP. The score ranges from 0 to 48, with higher scores indicating better functional ability.

    Time frame: Baseline, Up to 48 Weeks

  32. CIDP: Change From Baseline Over Time in 24-Item I-RODS Score

    I-RODS is a scale that assesses activity and participation limitations in people with CIDP. The score ranges from 0 to 48, with higher scores indicating better functional ability.

    Time frame: Up to 2 years

  33. CIDP: Change From Baseline Over Time in Medical Research Council (MRC) Sum Score

    MRC Sum Score is a measure to assess muscle strength for people with CIDP. The score ranges from 0 to 60. Higher scores indicate better muscle strength, while lower scores reflect greater weakness.

    Time frame: Up to 2 years

  34. CIDP: Change From Baseline Over Time in Adjusted INCAT Score

    INCAT is a tool used to assess functional disability in participants with CIDP. The total score ranges from 0 to 10, where higher scores indicate greater disability.

    Time frame: Up to 2 years

  35. CIDP: Change From Baseline Over Time in Timed Up and Go (TUG) Score

    TUG test is a measure of mobility, balance, and fall risk. The score is recorded in seconds; shorter times indicate better mobility, while longer times suggest impaired balance or gait.

    Time frame: Up to 2 years

  36. CIDP: Change From Baseline Over Time in Mean grip strength assessed by Martin Vigorimeter

    Mean Grip Strength is a quantitative measure of hand and forearm muscle strength. Higher values indicate better muscle strength, while lower values reflect weakness or functional impairment.

    Time frame: Up to 2 years

  37. Levels of T-cells in Blood

    Time frame: Up to 2 years

  38. Pharmacokinetics: Levels of Chimeric Antigen Receptor (CAR) T-cells in Blood

    Time frame: Up to 2 years

  39. Pharmacodynamics Parameters: Levels of B cells in Blood

    Time frame: Up to 2 years

  40. Pharmacodynamics Parameters: Levels of Disease-Specific Biomarkers and Autoantibodies in Blood

    Time frame: Up to 2 years

  41. Pharmacodynamics Parameters: Levels of Cytokines and Chemokines in Blood

    A panel of inflammatory, immuno-modulatory and effector molecules, including cytokines and chemokines, will be measured as units of concentration in serum (e.g. pg/ml) using ligand-based immunoassays such as MSD, Ella and O-link.

    Time frame: Up to 2 years

  42. Proportion of Participants With of Antibodies Against the KITE-363 CAR T cells in Blood

    Time frame: Up to 2 years

07

Study locations

8 of 8 sites recruiting
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92663, United States
    Recruiting
  • Stanford Neuroscience Health Center
    Palo Alto, California 94304, United States
    Recruiting
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
    Recruiting
  • LDS Hospital - Intermountain Health
    Salt Lake City, Utah 84143, United States
    Recruiting
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
    Recruiting
  • Concord Repatriation General Hospital
    Sydney, New South Wales 2139, Australia
    Recruiting
  • Corner Hawkesbury Road and Darcy Road
    Westmead, New South Wales 2145, Australia
    Recruiting
  • Jewish General Hospital
    Montreal, H3T 1E2, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07304154
Lead sponsor
Kite, A Gilead Company
Responsible party
Sponsor
First posted
Dec 26, 2025
Start date
Apr 10, 2026
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Aug 14, 2026

Study contacts

Medical Information
Contact
medinfo@kitepharma.com
844-454-5483(1-844-454-KITE)
Kite Study Director
study director · Kite, A Gilead Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating→

Other studies from this sponsor

Kite, A Gilead Company

Start the discussion